Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of cobimetinib alone or in combination with venetoclax and atezolizumab in multiple myeloma
2017-000830-68Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cobimetinib in multiple myeloma (MM) (3 arms), sponsored by Roche. Primary endpoints: Incidence, nature, and severity of adverse events and Laboratory safety parameters. Started Aug 2017; status: completed.
02
Drugs
cobimetinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-000830-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000830-68.